Actualización en el tratamiento de Helicobacter pylori: revisión del LATAMGCHMSG
DOI:
https://doi.org/10.47892/rgp.2024.444.1797Palabras clave:
Helicobacter pylori, Cáncer Gástrico, Terapéutica, Pruebas Diagnósticas de RutinaResumen
El Helicobacter pylori (H. pylori) es el principal agente etiológico del adenocarcinoma gástrico, el cual afecta a más del 60% de la población mundial y con una prevalencia importante en América latina. Debido a sus consecuencias en la población afectada, es importante conocer las herramientas disponibles para establecer el diagnóstico de esta infección. Si bien, las terapias asociadas a claritromicina aún son ampliamente utilizadas, las importantes tasas de resistencia a este antibiótico en la región obligan a establecer como estándar de tratamiento otras terapias de mejor eficacia, como la cuadriterapia con bismuto o la terapia dual con amoxicilina en altas dosis. En el caso de pacientes con infección refractaria, los registros de datos locales son de utilidad para la toma de decisiones.
Descargas
Métricas
Citas
Katelaris P, Hunt R, Bazzoli F, Cohen H, Fock KM, Gemilyan M, et al. Helicobacter pylori World Gastroenterology Organization Global Guideline. J Clin Gastroenterol. 2023;57(2):111-126. doi: 10.1097/MCG.0000000000001719.
Cardos AI, Maghiar A, Zaha DC, Pop O, Fritea L, Miere Groza F, et al. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics (Basel). 2022;12(2):508.
Sugano K, Tack J, Kuipers EJ. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64:1353-67.
Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature. 2007;445(7130):915-918.
Warren RJ, Marshall BJ. Unidentified curved bacilli in gastric epithelium in active chronic gastric. Lancet. 1983;1:1273-5.
Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. doi: 10.1136/gutjnl-2022-327745.
Besséde E, Mégraud F. Microbiota and gastric cancer. Sem Cancer Biology. 2022; 86:11-7.
Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69(12):2093-2112.
IARC Helicobacter pylori Working Group 2014. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8) [Internet]. Ginebra: WHO; 2014 [citado el 2 de agosto de 2024]. Disponible en: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php
Engstrand L, Graham DY. Microbiome and Gastric Cancer. Dig Dis Sci. 2020;65(3):865-873.
Graham DY. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014; 20(18): 5191-5204.
Jaroenlapnopparat A, Bhatia K, Coban S. Inflammation and Gastric Cancer. Diseases. 2022;10:35.
El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, et al. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol. 2018;16:992-1002.
Aguilera Matos I, Diaz Oliva SE, Escobedo AA, Villa Jiménez OM, Velazco Villaurrutia YDC. Helicobacter pylori infection in children. BMJ Paediatr Open. 2020;4(1):e000679.
Gong H, Xu HM, Zhang DK. Front Cell Focusing on Helicobacter pylori infection in the elderly. Infect Microbiol. 2023;13:1121947.
Robinson K, Atherton JC. The Spectrum of Helicobacter-Mediated Diseases. Annu Rev Pathol. 2021;16:123-144.
Assumpção PP, Barra WF, Ishak G, Coelho LGV, Coimbra FJF, Freitas HC, et al. The diffuse-type gastric cancer epidemiology enigma. BMC Gastroenterol. 2020;20(1):223
Rugge M, Genta RM, Di Mario F, El-Omar EM, El-Serag HB, Fassan M, et al. Gastric Cancer as Preventable Disease. Clin Gastroenterol Hepatol. 2017;15(12):1833-1843.
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. Lancet Glob Health. 2020;8:e180-90.
Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-analysis Gastroenterology. 2017;153(2):420-429.
Curado MP, Moura de Oliveira M, de Araújo Fagundes M. Prevalence of Helicobacter pylori infection in Latin America and the Caribbean populations: A systematic review and meta-analysis. Cancer Epidemiol. 2019;60:141-8.
Cho J, Prashar A, Jones NL, Moss SF. Helicobacter pylori Infection. Gastroenterol Clin North Am. 2021;50(2):261-282).
Leja M, Grinberga-Derica I, Bilgilier C, Steininger C. Review: epidemiology of helicobacter pylori infection. Helicobacter. 2019;24(Suppl 1):e12635.
Pérez G. Infección por Helicobacter pylori: mecanismos de contagio y prevención. Gastroenterol Latinoam. 2018;29:(Supl 1):13S-20S.
Duan M, Li Y, Liu J, Zhang W, Dong Y, Han Z, et al. Transmission routes and patterns of helicobacter pylori. Helicobacter. 2023 Feb;28(1):e12945. doi: 10.1111/hel.12945.
Iwai K, Watanabe I, Yamamoto T, Kuriyama N, Matsui D, Nomura R, et al. Association between Helicobacter pylori infection and dental pulp reservoirs in Japanese adults. BMC Oral Health. 2019;19(1):267. doi: 10.1186/s12903-019-0967-2.
Dore MP, Graham DY. Modern approach to the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther. 2022;55 Suppl 1:S14-S21.
Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biom J. 2016;39:14-23.
Wizenty J, Tacke F, Sigal M. Responses of gastric epithelial stem cells and their niche to Helicobacter pylori infection. Ann Transl Med. 2020;8(8):568.
Backert S, Neddermann M, Maubach G, Naumann M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2016;21(Suppl. 1):19-25.
Chmiela M, Kupcinskas J. Review: Pathogenesis of Helicobacter pylori infection. Helicobacter. 2019;24(Suppl. 1):e12638.
Gu H. Role of flagella in the pathogenesis of Helicobacter pylori. Curr Microbiol. 2017;74(7):863-869.
Waskito LA, Salama NR, Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2018;23(Suppl. 1):e12516.
Roshrosh H, Rohana H, Azrad M, Leshem T, Masaphy S, Peretz A. Impact of Helicobacter pylori virulence markers on clinical outcomes in adult populations. World J Gastroenterol. 2023;29(1):190-199.
Prada CF, Casadiego MA, Freire CC. Evolution of Helicobacter spp: variability of virulence factors and their relationship to pathogenicity. PeerJ. 2022;10:e13120. doi: 10.7717/peerj.13120.
Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022;53(1):33-50. doi: 10.1007/s42770-021-00675-0.
Becker KW, Skaar EP. Metal limitation and toxicity at the interface between host and pathogen. FEMS Microbiol Rev. 2014;38(6):1235-1249.
Camilo V, Sugiyama T, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2017;22:e12405.
Ha NC, Oh ST, Sung JY, Cha KA, Lee MH, Oh BH. Supramolecular assembly and acid resistance of Helicobacter pylori urease. Nat Struct Biol. 2001;8(6):505-509.
Javed S, Skoog EC, Solnick JV. Impact of Helicobacter pylori Virulence Factors on the Host Immune Response and Gastric Pathology. Curr Top Microbiol Immunol. 2019;421:21-52. doi: 10.1007/978-3-030-15138-6_2.
Dore MP, Pes GM. What Is New in Helicobacter pylori Diagnosis. An Overview. J Clin Med. 2021;10(10):2091.
Yan H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel). 2021;11(8):1305. doi: 10.3390/diagnostics11081305.
Dore MP, Graham DY. Modern approach to the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther. 2022;55 Suppl 1: S14-S21.
Lee YC, Dore MP, Graham DY. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. 2022;73:183-195.
Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: Can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med. 2009;151:121-8.
Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7(7):CD005583. doi: 10.1002/14651858.CD005583.pub3.
Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70(2):243-250.
Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150:1113-24.
Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS. Risk factors and incidence of gastric cancer after detection of Heicobacter pylori infection: A large cohort study. Gastroenterology. 2020;158:527-36.
Lin Y, Kawai S, Sasakabe T, Nagata C, Naito M, Tanaka K, et al. Effects of Helicobacter pylori eradication on gastric cancer incidence in the Japanese population: a systematic evidence review. Jpn J Clin Oncol. 2021;51(7):1158-1170. doi: 10.1093/jjco/hyab055.
Otero W, Buitrago J, Otero L. Helicobacter pylori: ¿Cómo tratarla en América Latina en el 2019? Revista GEN. 2019;73(3):90-98.
Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22(4). doi: 10.1111/hel.12392.
Morcillo JA, Otero W, Gómez M. Helicobacter pylori: ¿cómo mejorar las terapias de erradicación. Rev Col Gastroenterol. 2018;33(4):437-47.
Rugge M, Sugano K, Scarpignato C, Sacchi D, Oblitas WJ, Naccarato AG. Gastric cancer prevention targeted on risk assessment: Gastritis OLGA staging. Helicobacter. 2019;24(2):e12571.
Graham DY. Transitioning of Helicobacter pylori therapy from trial and error to antimicrobial stewardship. Antibiotics (Basel). 2020;9(10):671. doi: 10.3390/antibiotics9100671.
Graham DY, Megraud F. Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy. Helicobacter. 2021;26(1):e12773.
Graham DY, Liou JM. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antibiotic Stewardship. Clin Gastroenterol Hepatol. 2022;20(5):973-983.e1. doi: 10.1016/j.cgh.2021.03.026.
Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes [Internet]. Silver Spring, MD: Food and Drug Administration; 2018 [citado el 2 de agosto de 2024]. Disponible en: https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side
European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. European Medicines Agency; 2018 [citado el 2 de agosto de 2024]. Disponible en: https://www.ema.europa.eu/en/documents/referral/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-res-trictions-quinolone-and-fluoroquinolone-antibiotics_en.pdf
Gisbert JP. Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens. 2020;10(1):15.
Food and Drug Administration. FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults. Silver Spring, MD: Food and Drug Administration; 2019 [citado el 2 de agosto de 2024]. Disponible en: https://www.drugs.com/newdrugs/fda-approves-talicia-omeprazole-magnesium-amoxicillin-rifabutin-h-pylori-infection-adults-5098.html
Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus I. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020;172(12):795-802.
Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22(4). doi: 10.1111/hel.12392.
Morcillo JA, Otero W, Gómez M. Helicobacter pylori: ¿cómo mejorar las terapias de erradicación. Rev Col Gastroenterol. 2018;33(4):437-47.
Ierardi E, Losurdo G, Fortezza RF, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol. 2019;25(34):5097-5104.
Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter. 2019;24:e12554.
Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara. Meta-analysis: High-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-877.
De Francesco V, Ridola L, Hassan C, Bellesia A, Alvaro D, Vaira D, et al. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication. J Gastrointestin Liver Dis. 2016;25:147-150.
Furuta T, Graham DY. Pharmacologic aspects of eradicaction therapy for Helicobacter pylori infection. Gastroenterol Clin North Am. 2010;39:465-80.
Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423.
Arévalo-Galvis A, Otero-Regino WA, Ovalle-Celis GN, Rodríguez-Gómez ER, Trespalacios-Rangel AA. Prevalence of CY-P2C19 polymorphism in Bogotá, Colombia: The first report of allele *17. PLoS One. 2021;16(1):e0245401.
Howden CW, Graham DY. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021;116(1):1-3
Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, et al. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis. Digestion. 2021;102(3):319-325.
Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel). 2020;13(10):276.
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022;163(3):608-619.
Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015;42:922-33.
Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870-8.
Han Z, Li Y, Kong Q, Liu J, Wang J, Wan M, et al. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis. Helicobacter. 2022;27(6):e12930.
Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50:1185-90.
Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, et al. Helicobacter pylori second–line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015;41:768-75.
McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol. 2020;18(1):89-98
Cho J, Prashar A, Jones NL, Moss SF. Helicobacter pylori Infection. Gastroenterol Clin N Am. 2021;50:261-282.
Gao W, Xu Y, Liu J, Wang X, Dong X, Teng G, et al. A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies. Helicobacter. 2023;28(2):e12947. doi: 10.1111/hel.12947.
Graham DY, Moss SF. Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why. Am J Gastroenterol. 2022;117(4):524-528.
Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49(11):1385-1394.
Yu L, Luo L, Long X, Liang X, Ji Y, Chen Q, et al. Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Therap Adv Gastroenterol. 2019;12:1756284819874922. doi: 10.1177/1756284819874922.
Nyssen OP, Espada M, Gisbert JP. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Microbiol. 2022;13:913436. doi: 10.3389/fmicb.2022.913436.
Rokkas T, Ekmektzoglou K, Graham DY. Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis. Helicobacter. 2023;28(1):e12936.
Yu L, Luo L, Long X, Liang X, Ji Y, Graham DY, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019;24(4):e12596.
O’Connor A, Liou JM, Gisbert JP, O’Morain C. Review: Treatment of Helicobacter pylori Infection 2019. Helicobacter. 2019;24 Suppl 1:e12640.
Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4): e12692.
92Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, et al. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter. 2021;26(2):e12788.
Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet. 2010;375:248-251.
Laudanno O, Ahumarán G, Thomé M, Gollo P, Khoury M. Erradicación del Helicobacter pylori en pacientes obesos pre-cirugía bariátrica. Acta Gastroenterol Latinoam. 2020;50(1):40-4.
Laudanno O, Gollo P, Ahumarán G, Khoury M, Thomé M, González P. Tratamiento individualizado de erradicacion del Helicobacter pylori en pacientes obesos precirugía bariátrica. Rev Esp Enferm Dig. 2021;113(5):345-7.
Laudanno O, Riquelme A, Ahumaran G, Thome M. 268 Efficacy and safety of a tailored helicobacter pylori eradicacion therapy based on high-dose amoxicillin in obese patients. a post-hoc analysis of two multicenter prospective cohort studies. Gastroenterology. 2023;164(6):S-47.
Moss SF, Shah SC, Tan MC, El-Serag HB. Evolving Concepts in Helicobacter pylori Management. Gastroenterology. 2024;166(2):267-283
Arancibia A, Guttmann J, González G, González C. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother. 1980;17:199-202,
Aumpan N, Issariyakulkarn N, Mahachai V, Graham D, Yamaoka Y, Vilaichone R. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023;18(11):e0294403.
Buitrago Laguado J, Ruiz Linares C, Otero Regino W. Eficacia de la terapia dual, para erradicar Helicobacter pylori en una población colombiana. Acta Med Col. 2021;46(4):1-7 doi: 10.36104/amc.2021.2091.
Reyes D, Ortiz J, Fuentes-López E, Budnik S, Gándara V, Gallardo A, et al. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterol Hepatol. 2022;45(7):515–23.
Tursi A, Franceschi M, Allegretta L, Savarino E, De Bastiani R, Elisei W, et al. Effectiveness and safety of Pylera® in patients infected by Helicobacter pylori: a multicenter, retrospective, real life study. Dig Dis. 2018;36(4):264-8.
Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160(5):1831-41.
Viilalón A, Reyes D, Ortiz J, Gándara V, Díaz LA, Chahuán J, et al. Tratamiento y manejo de la infección por Helicobacter pylori. Gastroenterol Latinoam. 2020;31(3):136-146.
Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, et al. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol. 2021;116(6):1220-1229. doi: 10.14309/ajg.0000000000001246.
Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102:493-6.
Kotilea K, Mekhael J, Salame A, Mahler T, Miendje-Deyi VY, Cadranel S, et al. Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22:e12383.
Nyssen OP, Vaira D, Tepes B, Kupcinskas L, Bordin D, Pérez-Aisa Á, et al. Room for improvement in the treatment of Helicobacter pylori infection: Lessons from the European registry on H. pylori management (Hp-EuReg). J Clin Gastroenterol. 2022;56(2):e98-e108. doi: 10.1097/MCG.0000000000001482.
McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Pérez-Aisa Á, Modolell I, et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: a randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):e12529.
Zagari RM, Romiti A, Ierardi E, Gravina AG, Panarese A, Grande G, et al. The “three-in-one” Formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: efficacy and safety in daily clinical practice. Helicobacter. 2018;23(4):e12502.
Graham DY. Editorial--Avoiding Unethical Helicobacter pylori Clinical Trials: Susceptibility-Based Studies and Probiotics as Adjuvants. Helicobacter. 2015;20(5):321-325.
Otero W, Trespalacios AA, Otero L, Vallejo MT, Torres Amaya M, Pardo R, et al. Guía práctica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Col Gastroenterol. 2015;30(Suppl. 1):17-33.
Corral JE, Mera R, Dye CW, Morgan DR. Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer prevention. World J Gastrointest Oncol. 2017;9(4):184-193.
Otero W, Trespalacios AA, Mercado M. Tasa de reinfección por Helicobacter pylori en una cohorte de pacientes colombianos tratados exitosamente con seguimiento superior a 2 años. Rev Col Gastroenterol. 2015;30:53-59.
Zhao JB, Yuan L, Yu XC, Shao QQ, Ma J, Yu M,et al. Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis. Helicobacter. 2021;26(3):e12793. doi: 10.1111/hel.12793.
Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, et al. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology. 2018;155(1):67-75
Matsushima R, Matsushima S, Kobayashi M, Fujimori K, Sakamoto N, Asaka M. An increasing trend of gastric cancer deaths and inadequate preventive measures in elderly adults. Helicobacter. 2023;28(4):e12988
Ferreccio C, Rollán A, Harris PR, Serrano C, Gederlini A, Margozzini P, et al. Gastric cancer is related to early Helicobacter pylori infection in a high-prevalence country. Cancer Epidemiol Biomarkers Prev. 2007;16:662-667.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 William Otero R., Arnoldo Riquelme, José María Remes-Troche, Oscar Laudanno, Alejandro Piscoya, Hernando Marulanda, Lina Otero, Diego Reyes-Placencia
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
2022 